The Leukemia & Lymphoma Society of Canada and The Canadian Cancer Survivor Network are seeking patient and caregiver input for the pan-Canadian Oncology Drug Review (pCODR) which will be reviewing an upcoming submission for ibrutinib (Imbruvica) for relapsed/refractory mantle cell lymphoma (MCL).
We invite you to help the drug submission reviewers better understand what it is to like to live with MCL by sharing your experiences. While this is a Canadian drug review process, survey responses are welcome from people impacted by MCL anywhere in the world. Please forward this email to anyone you know who is diagnosed with or providing care for someone with MCL.
Click on the appropriate survey for your situation.
1. Survey for patients diagnosed with MCL https://www.surveymonkey.com/r/9JLNJZ5
2. Survey for MCL caregivers https://www.surveymonkey.com/r/9CJFCQP
The information you provide will remain anonymous. Your survey responses are helpful in informing the pCODR review process.
We greatly appreciate your participation in this survey. If you have any questions or technical difficulties while completing this survey, please contact Sharon Paulse at email@example.com or 1.866.547.5433 and press 1 for Vancouver. (If you received a similar survey from another organization, you are still welcome to complete this survey, as pCODR allows submissions from various patient organizations.)
The deadline to complete this survey is January 31, 2016.